SOPHiA GENETICS
Healthcare technology company providing data-driven medicine solutions through AI-powered genomic and radiomic analysis, enabling healthcare institutions worldwide to share and analyze clinical data. Publicly traded on NASDAQ (SOPH).
Location
Lausanne, Switzerland
Founded
2011
Investors
1
Categories
genomics, data-driven-medicine, ai, diagnostics, public-company
Notes
SOPHiA GENETICS is a healthcare technology company that provides data-driven medicine solutions, enabling healthcare institutions to share and analyze genomic and radiomic data through AI-powered analysis. The company is publicly traded on NASDAQ under the ticker symbol SOPH and is headquartered in Lausanne, Switzerland.
The company's SOPHiA DDM (Data-Driven Medicine) platform is used by hospitals and laboratories worldwide to:
- Analyze genomic data for cancer and hereditary disease diagnosis
- Perform radiomic analysis of medical images
- Share de-identified data across a global network of healthcare institutions
- Enable collaborative learning and improved diagnostic accuracy
SOPHiA GENETICS serves over 1,000 hospitals and laboratories across 70+ countries.
Team
- Jurgi Camblong, Ph.D. - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/jurgicamblong
- Pierre Hutter - Co-founder
- Lars Steinmetz, Ph.D. - Co-founder
Additional Research Findings
- NASDAQ: SOPH (publicly traded)
- Portfolio company of aMoon
- SOPHiA DDM platform for data-driven medicine
- AI-powered genomic and radiomic analysis
- 1,000+ hospital and laboratory customers
- 70+ countries served
- Lausanne, Switzerland headquarters
- Founded in 2011
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| aMoon | Tel Aviv, Israel | biotech-focused | series-aseries-b+2 | 8 |